Cerebellar ataxia and sensory ganglionopathy associated with light-chain myeloma

Panagiotis Zis\textsuperscript{1,2}\textsuperscript{*}, Dasappaiah Ganesh Rao\textsuperscript{1}, Bart E Wagner\textsuperscript{3}, Lucinda Nicholson-Goult\textsuperscript{3}, Nigel Hoggard\textsuperscript{4} and Marios Hadjivassiliou\textsuperscript{1,2}

Abstract

Background: Cerebellar ataxia with sensory ganglionopathy is a rare neurological combination that can occur in some hereditary ataxias including mitochondrial diseases and in gluten sensitivity. Individually each condition can be a classic paraneoplastic neurological syndrome. We report a patient with this combination who was diagnosed with light-chain myeloma ten years after initial presentation.

Case presentation: A 65-year-old Caucasian lady was referred to our Ataxia Clinic because of a 6-year history of progressive unsteadiness and a 2-year history of slurred speech. Past medical history included arterial hypertension. The patient was a non-smoker was not consuming alcohol excessively. There was no family history of ataxia. Neurological examination revealed prominent gaze-evoked nystagmus, heel to shin ataxia, gait ataxia, reduced reflexes and loss of vibration sensation in the legs. Cerebellar ataxia was confirmed using magnetic resonance spectroscopy of the cerebellum and sensory ganglionopathy using neurophysiological assessments including blink reflex study. A muscle biopsy that was arranged to explore the possibility of mitochondrial disease revealed amyloidosis. Urinalysis confirmed the presence of light chains. A bone marrow biopsy confirmed the diagnosis of light chain multiple myeloma.

Conclusions: Whilst it could be argued that this could simply be a coincidence, the rarity of these conditions and the absence of an alternative aetiology for the neurological dysfunction argue in favour of a paraneoplastic phenomenon.

Keywords: Sensory ganglionopathy, Ataxia, Cerebellar, Amyloid, Myeloma, Paraneoplastic

Background

Ataxia is a term used to describe poor control of movement, which manifests with unsteadiness and poor co-ordination. Ataxia can be mainly classified into cerebellar and sensory.

Cerebellar ataxia, resulting from a dysfunction of the cerebellum, can be inherited (e.g. Friedreich’s ataxia and spinocerebellar ataxias, known as SCAs) or acquired (such as immune mediated and paraneoplastic) [1]. Sensory ataxia results from a loss of proprioception and is usually caused by dysfunction within the sensory pathways, both peripheral and central. Sensory ataxia can therefore be seen in neuropathies that involve sensory fibers in isolation or in combination with motor fiber involvement. Sensory ataxia is more prominent in pure sensory neuropathies also called sensory neuropathies [2]. Causes for sensory neuropathies or neuropathies can be immune mediated [3] e.g. gluten sensitivity [4] Sjogren’s syndrome and paraneoplastic [5]. Cerebellar ataxia combined with sensory neuronopathy is a relatively rare neurological picture, which can be seen in some hereditary ataxias [2] (e.g. Friedreich’s ataxia and SCA18, mitochondrial disease) or as a result of exposure to toxins (e.g. amiodarone [6]).
We present a case with this combination with a rather unusual aetiology.

**Case presentation**

A 65-year-old Caucasian lady was referred to our Ataxia Clinic because of a 6-year history of progressive unsteadiness and a 2-year history of slurred speech. Past medical history included arterial hypertension. The patient was a non-smoker was not consuming alcohol excessively. There was no family history of ataxia.

Neurological examination revealed prominent gazed-evoked nystagmus, heel to shin ataxia, gait ataxia, reduced reflexes and loss of vibration sensation in the legs.

Routine blood tests included full blood count, erythrocyte sedimentation rate, urea, creatinine, electrolytes, liver function tests, thyroid function tests, random glucose, Vitamin B12, folate, Vitamin E and folate, were all normal.

Extensive immunology screening included immunoglobulins and serum electrophoresis, antinuclear antibodies (ANA), anti-double stranded DNA (anti-dsDNA) antibodies, GAD antibodies, anti-neutrophil cytoplasmic antibodies (ANCA), thyroid peroxidase (TPO) antibodies, endomysium antibodies, transglutaminase antibodies and gliadin antibodies. From those, the IgA and IgM titer were low (IgA 0.63 g/L, normal values 0.8–4.0 and IgM 0.22 g/L, normal values 0.5–2.0), with no electrophoretic abnormality noted. C-ANCA antibodies were positive but PR3 antibodies were negative. Interestingly, the patient had the DQ8 human leukocyte antigen (HLA) serotype, which is commonly linked to autoimmune diseases, including coeliac disease [7].

The MRI of the brain was unremarkable for the patient's age, with no evidence of cerebellar atrophy in particular. However, the magnetic resonance spectroscopy (MRS) of the cerebellar vermis revealed a low N-acetyl aspartate (NAA) to Creatine (Cr) area ratio (NAA/Cr 0.95, normal values [8] > 1.0) (Fig. 1A). Low NAA/Cr ratio implies abnormal metabolic activity within the area of interest (voxel). It can be used as an indicator to cerebellar dysfunction [9].

Sensory conduction studies of the right median, right ulnar, right radial and both sural nerves showed attenuated amplitudes, when the motor conduction studies of the right median, right ulnar and right peroneal nerves were within normal limits. The electrically elicited blink reflex was tested bilaterally and revealed an asymmetric involvement of the trigeminal/facial nerve pathways, suggesting a diagnosis of sensory ganglionopathy [10].

As the combination of cerebellar ataxia with sensory ganglionopathy can be seen as part of hereditary ataxias, including mitochondrial diseases, the patient was initially tested and was negative for the common genetic ataxias (Fridriech's ataxia, SCA1, SCA2, SCA3, SCA6 and SCA7). Subsequent further genetic testing using new generation sequencing was also negative and included the following genes; ABCB7, AFG3L2, APTX, ATM, ATP1A2, ATP1A3, ATP7B, C10orf2, CACNA1A, CACNB4, CYP2U1, CYP27A1, DDHD2, EEF2, FGF14, FTL, FXY, GBA, GBA2, IFRD1, ITPR1, KCNA1, KCNC3, KCND3, MTPAP, PDYN, PRKCG, PRRT2, SACS, SCN1A, SETX, SLI1, SLC16A2, SLC1A3, SLC2A1, SPG7, SPTBN2, TGM6, TTBK2, TPPA, VAMP1, ZFYVE26 (Additional file 1).

**Clinical course**

The patient has been followed-up on a 6 monthly basis and remained relatively stable. Thirty months after the initial presentation to our clinic repeat nerve conduction studies and repeat MRI and MRS were arranged. The nerve conduction studies showed further deterioration of the sensory ganglionopathy. The MRI of the brain showed is mild to moderate atrophy of the vermis [11] (grade 2) and mild atrophy [11] (grade 1) of the hemispheres (Fig. 2), when the MRS showed further deterioration of the NAA/Cr ratios of the cerebellum (Fig. 1B).

In order to rule out mitochondrial disease the common mitochondrial mutations (MELAS, MERRF, NARP, POLG1) were tested and were negative and a muscle biopsy was arranged. Transmission electron microscopy of glutaraldehyde fixed muscle revealed the presence of endomysial amyloid. Histologically, no inflammation, necrosis, or inclusions were seen (Fig. 3). Urinalysis confirmed the presence of light chains. A bone marrow biopsy was performed confirming the diagnosis of light chain multiple myeloma. Scintigraphy showed predominantly cardiac involvement and the patient was referred for further treatment.

Table 1 summarizes the nerve conduction tests and the MRS findings across the clinical course of the patient.

**Discussion**

Despite the extensive diagnostic work up for cerebellar ataxia combined with sensory ganglionopathy our patient was only diagnosed with light-chain multiple myeloma 10 years after the onset of the neurological symptoms. Until then, our working diagnosis based on extensive investigations was idiopathic sporadic cerebellar ataxia with sensory ganglionopathy, possibly autoimmune mediated.

Light-chain myeloma accounts for about 20% of multiple myeloma cases [12]. Three quarters of the light-chain myelomas are of kappa light chain and in only 25% the histological finding is the deposition of lambda light chain [12]. Therefore, the lambda light chain myeloma accounts for the only 5% of all multiple myeloma cases.
Neurological manifestations of light chain myeloma can be central or peripheral. Central manifestations most commonly result from cerebral or cerebellar plasmacytomas [13]. Occasionally patients may present with myelopathy secondary to paraspinal plasmacytomas [14]. Peripheral manifestations include radiculopathy secondary to fractures of the vertebrae, amyloid neuropathy and peripheral neuropathies related to a remote effect of the monoclonal gammapathy or to amyloidosis, in addition to the neurotoxicity of treatments, such as thalidomide and bortezomib [15].

Amyloid neuropathy occurs secondary to deposition of amyloid in the peripheral nerves. It usually leads to a symmetrical sensorimotor axonal neuropathy almost always with autonomic involvement. In our case, as implied by the nerve conduction studies, the pathology had to be confined to the dorsal root ganglia. In addition the patient had no autonomic dysfunction. It is therefore highly unlikely that the sensory ganglionopathy, that the patient had, was related to the amyloidosis.

Sub-acute sensory ganglionopathy as a paraneoplastic phenomenon is commonly associated with small cell lung cancer [16]. Other tumors associated with paraneoplastic sensory neuronopathy include breast cancer, prostate cancer, ovarian cancer, bladder cancer, Hodgkin Lymphoma and sarcoma [17]. Cerebellar degeneration as a paraneoplastic phenomenon is associated with a broad spectrum of tumors including ovarian cancer,

![Spectral data obtained at intermediate echo-time by single-voxel 1H magnetic resonance spectroscopy of the cerebellar vermis. The amplitude of the resonances is measured on the Y-axis using an arbitrary scale. A low N-acetyl aspartate (NAA) to creatine (Cr) area ratio was found at first assessment with NAA/Cr 0.95, normal values >1.08 (A). MRS findings at 30 months show deterioration of NAA/Cr with a drop from 0.95 to 0.83 (B).](Fig_1)
breast cancer, lung cancer and Hodgkin’s lymphoma [18]. To our knowledge, multiple myeloma has not been linked to any paraneoplastic neurological syndrome.

The recommended diagnostic criteria for paraneoplastic neurological syndromes [19] suggest that the cancer has to develop within five years of the diagnosis of neurological disorder. This time period has been based on reports showing that in the majority of cases the interval between the paraneoplastic neurological syndrome and the diagnosis of cancer is less than 5 years. In our case, the interval between the onset of the neurological symptoms and the diagnosis of the malignancy was ten years.

Conclusions
To our knowledge this is the first case of cerebellar ataxia with sensory ganglionopathy associated with light chain myeloma. Whilst it could be argued that this could simply be a coincidence, the rarity of these conditions and the absence of an alternative aetiology for the neurological dysfunction argues in favour of a paraneoplastic phenomenon. As the myeloma in this case is not curable the chances of recovery with chemotherapy are remote. Indeed on the latest MR imaging there is significant progression of the spectroscopic abnormalities as well as the development of cerebellar atrophy.
|                      | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and | Neurological dysfunction in coeliac disease and |
|----------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| **Baseline**         | 11.7                                          | 88                                            | 63                                            | X                                             | 0.8                                           | 0.8                                           | 2.9                                           | 0.7/0.7                                       | 106/163                                       | 60.5/55.3                                      |
| F/U at 30 m          | 104                                           | X                                             | 44                                            | 11.1                                          | NR                                           | 0.5                                           | NR                                           | NR                                           | X                                             | X                                             |
| F/U at 42 m          | 107                                           | 66                                            | 35                                            | 11.1                                          | NR                                           | NR                                           | NR                                           | NR                                           | X                                             | X                                             |
| F/U at 54 m          | X                                             | X                                             | X                                             | X                                             | X                                             | X                                             | X                                             | X                                             | X                                             | X                                             |

CMAP: compound muscle action potential, SNAP: sensory nerve action potential, L: Left, R: Right, NR: no response, X: not done
Median and ulnar studies - orthodromic, radial, peroneal and sural - antidromic
$cR2 = contralateral R2; iR2 = ipsilateral R2$
Additional file

Additional file 1: Ataxia panel performed. Diseases corresponding to the genes tested. (DOCX 104 kb)

Abbreviations
ANA: Antinuclear antibodies; ANCA: Anti-neutrophil cytoplasmic antibodies; Cr: Creatine; dsDNA: Double stranded Deoxyribonucleic acid; GAD: Glutamic acid decarboxylase; MELAS: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF: Myoclonic Epilepsy with Ragged Red Fibers; MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; NAA: N-acetyl aspartate (NAA); NARP: Neuropathy, ataxia, and retinitis pigmentosa; SCA: Spinocerebellar ataxia; TPO: Thyroid peroxidase

Acknowledgements
None.

Funding
None.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions
PZ and MH drafted the manuscript. DGR performed the neurophysiological studies. BEW and LNG performed the pathological examinations of the muscle biopsy. NH reported all sequential imaging examinations. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Ethics approval and consent to participate
Not applicable.

Author details
1Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 2University of Sheffield, Royal Hallamshire Hospital, Royal Hallamshire Hospital, Glossop Rd, Sheffield, South Yorkshire S10 2JF, UK. 3Histopathology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 4Department of Neuroradiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Received: 2 October 2016 Accepted: 12 December 2016
Published online: 05 January 2017

References
1. Ramirez-Zamora A, Zeigler W, Desai N, Biller J. Treatable causes of cerebellar ataxia. Mov Disord. 2015;30:614–23.
2. Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol. 2005;4:349–61.
3. Zis P, Sarrigiannis PG, Rao DG, Hewartadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol. 2016; 263(10):1903–10.
4. Hadjivassiliou M, Rao DG, Grunevald RA, Aeschlimann DP, Sarrigiannis PG, Hoggard N, et al. Neurological dysfunction in coeliac disease and non-coeliac gluten sensitivity. Ann J Gastroenterol. 2016;111(4):561–7.
5. Scaravilli F, An SF, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol. 1999;9:251–60.
6. Hillier DN, Miller MA, Parker R, Doering F, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998;18:138s–45s.
7. Green PH, Jabari B. Coeliac disease. Lancet (London, England). 2003;362:383–91.
8. Currie S, Hadjivassiliou M, Craven I, Wilkinson ID, Griffiths PD, Hoggard N. Magnetic resonance spectroscopy of the brain. Postgrad Med. J. 2013;89:94–106.
9. Shanmugarajah PD, Hoggard N, Currie S, Aeschlimann DP, Aeschlimann PC, Gleeson DC, Karajeh M, Woodroffe N, Grunevald RA, Hadjivassiliou M. Alcohol-related cerebellar degeneration: not all down to toxicity? Cerebellum Ataxias. 2016;3:17. eCollection 2016.
10. Alam T, Barker AS, Alix JJ, Hadjivassiliou M, Rao DG. Sensory ganglionopathy and the blink reflex: electrophysiological features. Can J Neurol Sci. 2016;43(3):385–9.
11. Hadjivassiliou M, Wallis LJ, Hoggard N, Grunevald RA, Griffiths PD, Wilkinson ID. MR spectroscopy and atrophy in gluten, friedreich’s and SCA6 ataxias. Acta Neurol Scand. 2012;126(2):138–43.
12. Pavan M, Ashwini KA, Ravi R, Sudatkal LH. Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids. Indian J Nephrol. 2010;20:94–6.
13. Wavre A, Baur AS, Betz M, Mühlematter D, Jotterand M, Zaman K, et al. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma. Neuro Oncol. 2007;9(3):370–2.
14. Kumar A, Satyarthee GD, Sable M, Suri V, Sharma BS. Solitary extramedullary plasmacytoma of thoracic epidural space presenting with dorsal compressive myelopathy: A case report and review of literature. J Neurosci Rural Pract. 2015;6:410–2.
15. Denier C, Lozeron P, Adams D, Decaudin D, Isnard-Grivaux F, Lacroix C, et al. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology. 2006;66:917–8.
16. Dalmaj J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuropathy. A clinical study of 71 patients. Medicine. 1992;71:159–72.
17. Gwathmey KG. Sensory neuropathies. Muscle Nerve. 2016;53:18–19.
18. Dalmaj J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–40.
19. Graus F, Delattre JJ, Antoine JC, Dalmau J, Grommet B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.